Sign in
LTRN Stock Price, Chart, Stats & News
Lantern Pharma Inc.
Save
Lantern Pharma Inc. (LTRN) does not currently pay a dividend.
15.44M
Market cap
–
Current P/E
–
Forward P/E
LTRN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -138.85% |
ROE | -125.98% |
D/E | 0.01x |
Interest coverage ratio | – |
LTRN valuation
P/E | – |
P/S | – |
P/B | 1.27x |
P/CF | -0.72x |
P/FCF | -0.74x |
P/OCF | -0.72x |
PEG | -0.38x |
EV multiple | -1.07x |
About
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked.
Similar securities
Based on sector and market capitalization
Report issue